Matthew Seymour, MD: A Clinical Trialist’s Perspective

First International Summit on Interventional Pharmacoeconomics

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Issues in Oncology

Cost of Care

The ASCO Post Staff

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Mark J. Ratain, MD, of the University of Chicago, and Daniel Goldstein, MD, of the Rabin Medical Center, discuss the challenges of achieving cancer care value, evolution of the “more-is-better” philosophy when it comes to oncology drugs, and highlights of the First International Summit on Interventional Pharmacoeconomics.

Apr

Today In Oncology

Matthew Seymour, MD: A Clinical Trialist’s Perspective

Related Videos

Russell Szmulewitz, MD, on Alternative Dosing of Abiraterone in Prostate Cancer: Pharmacoeconomic Proof of Concept

Cody Peer, PhD, on Simulating Alternative Schedules for Checkpoint Inhibitors

Ian Tannock, MD, PhD, DSc, on Near-Equivalence: A Better Question Than Non-Inferiority

S. Vincent Rajkumar, MD, on Cost-Effective Treatment of Multiple Myeloma

Mark J. Ratain, MD, and Daniel Goldstein, MD, on Value in Cancer Care: How the Paradigm Is Shifting

Neoadjuvant Durvalumab Plus Chemotherapy for High-Risk Upper Tract Urothelial Carcinoma

Early-Life Exposure to Environmental Carcinogens May Increase Risk of Pediatric Papillary Thyroid Cancer

Metabolic Syndrome May Increase Risk of Cancer Recurrence Subsequent Mortality Among Breast Cancer Survivors

Activity of ROS1 TKI in NSCLC

Some Patients With Advanced NSCLC Experience Durable Disease Control After Immunotherapy Discontinuation